Non-interventional Study -Observe Treatment Efficacy in Maintaining Symptoms Control in Schizophrenia With Seroquel XR

AstraZeneca578 enrolled

Overview

the primary purpose of the study is to observe symptoms control in schizophrenia for 6 months in patients treated with Seroquel XR. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Study Type

OBSERVATIONAL

Enrollment

578

Conditions

Schizophrenia

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients will have a diagnosis of schizophrenia , as defined by DSM-IV-TR and their symptoms are controlled with Seroquel XR therapy started approximately 1 month before * All eligible patients will be included in the protocol provided they will receive detailed information in advance and will sign consent to grant access to their own data collected during this programme. Exclusion Criteria: * All the patients who have a known hypersensitivity to Seroquel XR/quetiapine or any of its excipients will not be included in this study. * As per valid Romanian SmPC, concomitant medication, that could result in drug interactions and could jeopardise patient safety will be carefully considered before having the patient enrolled.

Locations (32)

Research Site

Alba, Romania

Outcomes

Primary Outcomes

Brief Psychiatric Rating Scale - BPRS

Time frame: monthly/ at every clinic visit- 7 times

Secondary Outcomes

Clinical Global Impression Severity of Illness - CGI -S

Time frame: monthly/ at every clinic visit- 7 times

Clinical Global Impression Improvement CGI -I

Time frame: monthly/ at every clinic visit except first visit- 6 times

Quality of Life Enjoyment & Satisfaction Questionnaire - Short Form ( Q - LES - Q - SF)

Time frame: twice/first and last clinic visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.